[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Firstkind Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100608164","the-retrain-trial-phase-2-100608164",false,"NCT07197996","The RETRAIN Trial Phase 2","MonitoRing the Effect of Intermittent Pneumatic Compression and TRAnscutaneous Functional electrIcal Stimulation of the Common Peroneal Nerve Using the Geko® Device on Cerebral Haemodynamics in Patients With Ischaemic Strokes (The RETRAIN Trial Phase 2)","RETRAIN 2","Inclusion Criteria:\n\n1. Adult over 18\n2. Patient with ischaemic stroke diagnosis confirmed by a stroke physician.\n3. Within 36 hours of symptom onset.\n4. Unable to stand or mobilise without assistance.\n5. No intracerebral haemorrhage as ruled out by computerised tomography (CT) or Magnetic Resonance Imaging (MRI) scan.\n\nExclusion Criteria:\n\n1. Inability to gain consent from the patient, or a declaration from a Personal Consultee or Nominated Consultee.\n2. Absence of a transient ischaemic attack (TIA).\n3. Clinically apparent deep vein thrombosis at screening\n4. Patient is expected to require palliative care within 14 days\n5. No response to the geko® device i.e. no involuntary rhythmic upward and outward movement of the foot (dorsiflexion) at the maximum tolerable device setting.\n6. Contraindications for the use of the geko™ device\n\n   * Allergy to hydrogel constituents\n7. Contraindications to IPC\n\n   * Severe peripheral vascular disease\n   * Large leg ulcers requiring extensive bandaging (small ulcers or skin breaks with flat coverings are not an exclusion)\n   * Severe oedema\n   * Leg deformities making appropriate fitting impossible\n   * Symptomatic congestive cardiac failure of NYHA class IV (symptoms of heart failure at rest, any physical activity causing further discomfort).\n8. Single or double leg amputations.\n9. Participation in any other clinical trial\n10. Patients must not have a current coronavirus (COVID-19) infection","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","Ischaemic strokes, caused by a disruption in the brain's blood supply, are the second leading cause of death and disability in the United Kingdom. This single-center prospective randomised study aims to measure cerebral blood flow and oxygen delivery in patients who have recently suffered an ischaemic stroke and are using either the geko® neuromuscular electrostimulation device or an intermittent pneumatic compression (IPC) device as part of their routine clinical care.\n\nThe geko® device stimulates a nerve in the lower leg, inducing muscle contractions that enhance blood circulation. The IPC device applies controlled external pressure through compressed air and a pump, cyclically inflating and deflating chambers in a sleeve worn on the leg. This mimics the action of calf muscles to promote blood flow.\n\nThe primary objective of this study is to assess the effect of the geko® and IPC devices on cerebral blood flow in stroke patients, specifically during the hyperacute phase (within 36 hours) following an ischaemic stroke. Both devices will be used as part of standard care for VTE prevention. Cerebral blood flow will be measured using functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG).",[27],"Ischaemic Stroke",[29,30,31,32,33,34],"Acute ischemic stroke","Neuromuscular electrostimulation","Effects on cerebral blood flow","Randomised controlled trial","Cerebral blood flow measurements","Stroke rehabilitation","RECRUITING","2025-09-25",{"date":38,"type":39},"2025-09-30","ACTUAL",{"date":41,"type":39},"2025-07-01",{"date":43,"type":21},"2026-07-01",{"name":45,"class":46},"Firstkind Ltd","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100475898","geko-venous-thromboembolism-prevention-study-100475898","NCT05476913","GEKO Venous Thromboembolism Prevention Study","A Randomised Controlled Trial of the Effectiveness of Intermittent Surface Neuromuscular Stimulation Using the Geko™ Device Compared With Intermittent Pneumatic Compression to Prevent Venous Thromboembolism in Immobile Acute Stroke Patients","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Clinical diagnosis of acute stroke (WHO criteria)\n3. Within 36 hours of symptom onset\n4. Not able to get up from a chair\u002Fout of bed and walk to the toilet without the help of another person\n\nExclusion Criteria:\n\n1. Inability to gain consent from the patient, or a declaration from a Personal Consultee or Nominated Consultee\n2. Unwitnessed onset with a long lie on the floor before admission\n3. Clinically apparent deep vein thrombosis at screening\n4. Patient is expected to require palliative care within 14 days\n5. Patient does not live in the local catchment area and is expected to be transferred to their local hospital for on-going care.\n6. Patient has recently been involved in or is currently involved in a clinical trial for either a medical device or medicinal product, within the past 3 months, with the exception: if co-enrolment is not considered to impact adverse events or outcomes in the opinion of the Chief Investigator. (A live document containing a list of approved studies will be included in a reference document made available to all study sites and available upon request)\n7. Contraindications for the use of the geko™ device:\n\n   * Allergy to hydrogel constituents\n8. Contraindications to IPC:\n\n   * Severe peripheral vascular disease\n   * Large leg ulcers requiring extensive bandaging (small ulcers or skin breaks with flat coverings are not an exclusion)\n   * Severe oedema\n   * Leg deformities making appropriate fitting impossible\n9. Uncontrolled congestive cardiac failure\n10. Pregnancy\n11. Single or double leg amputations",{"count":56,"type":21},1200,[24],"This multicentre, randomised geko™ venous thromboembolism (VTE) prevention study will prospectively collect clinical data on VTE occurrences in immobile patients after stroke, who will be randomised, on a 1:1 allocation, to receive either standard of care (Intermittent Pneumatic Compression) or geko™ neuromuscular electrostimulation device. The aim is to assess the prevention of VTE during a follow-up period of 90 days (three months) post-randomisation.",[60,61,62,63],"Stroke, Acute","Venous Thromboembolism","Deep Vein Thrombosis","Pulmonary Embolism",[65,66,60,61,63,67],"geko","intermittent pneumatic compression","DVT prophylaxis","2025-02-27",{"date":70,"type":39},"2025-03-04",{"date":72,"type":39},"2023-07-06",{"date":74,"type":21},"2025-06-30",{"name":45,"class":46},18,""]